News
X-ray Activated Nanoparticles Show Promise for Deep Tumour Immunotherapy
Researchers have developed X-ray preactivated nanoparticles that target deep-seated tumours. These nanoparticles, loaded with elimusertib, exhibit reversible "on-off" afterglow properties, enhancing immuno-photodynamic therapeutic efficacy in mice.
A study published in *Nature Communications* details a novel approach to photodynamic therapy (PDT) for deep tumours, using X-ray preactivated nanoparticles. The approach uses persistent luminescence, which provides sustained light within tissues, removing the need for continuous external illumination. The X-ray-activated nanoparticles continuously activate chlorin e6 (Ce6) to generate reactive oxygen species (ROS), leading to DNA damage in tumour cells. Integration of elimusertib with the nanoparticles potentiates ROS-induced DNA damage. This process also activates the cGAS-STING pathway, further boosting immuno-photodynamic therapeutic efficacy. Researchers highlight the potential of these nanoparticles to advance the treatment of deep-seated tumours, offering a platform for combined immuno-photodynamic therapy.
Key Facts
- The study introduces X-ray preactivated nanoparticles for photodynamic therapy of deep tumours.
- The nanoparticles feature reversible "on-off" afterglow properties for controlled light activation.
- The nanoparticles continuously activate chlorin e6 (Ce6) to generate reactive oxygen species (ROS), inducing DNA damage.
- The integration of elimusertib enhances ROS-induced DNA damage and activates the cGAS-STING pathway.
- Experiments were conducted in vivo using female mice.
- The new approach eliminates the need for continuous external illumination.
- The new method offers a controllable platform for combined immuno-photodynamic therapy.